Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.10% to 6,040.04 and the Dow Jones Industrial Average DJIA rising 0.91% to 43,297.03.

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

The new price target represents a nearly 10% premium to Netflix stock's current perch of $915.31 and is just above its Dec. 11 all-time high of $941.75. The equity is up 87.7% since the start of 2024,

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top